Advanced SearchSearch Tips
Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey
Arvas, Macit; Salihoglu, Yavuz; Sal, Veysel; Gungor, Tayfun; Sozen, Hamdullah; Kahramanoglu, Ilker; Topuz, Samet; Demirkiran, Fuat; Iyibozkurt, Cem; Bese, Tugan; Ozgu, Burcin Salman; Vatansever, Dogan; Tokgozoglu, Nedim; Berkman, Sinan; Turan, Hasan; Bengisu, Ergin; Sofiyeva, Nigar; Demiral, Irem; Meydanli, Mutlu;
  PDF(new window)
Background: The purpose of this study was to determine the benefit of tertiary cytoreductive surgery (TC) for secondary recurrent epithelial ovarian cancer (EOC), focusing on whether optimal cytoreduction has an impact on disease-free survival, and whether certain patient characteristics could identify ideal candidates for TC. Materials and Methods: Retrospective analysis of secondary recurrent EOC patients undergoing TC at three Turkish tertiary institutions from May 1997 to July 2014 was performed. All patients had previously received primary cytoreduction followed by intravenous platinum-based chemotherapy and secondary cytoreduction for first recurrence. Clinical and pathological data were obtained from the patients` medical records. Survival analysis was caried out using the Kaplan Meier method. Actuarial curves were compared by the two tailed Logrank test with a statistical significance level of 0.05. Results: Median age of the patients was 49.6 years (range, 30-67) and thirty-eight (72%) had stage III-IV disease at initial diagnosis. Twenty six (49%) had optimal and 27 (51%) suboptimal cytoreduction during tertiary debulking surgery. Optimal initial cytoreduction, time to first recurrence, optimal secondary cytoreduction, time interval between secondary cytoreduction and secondary recurrence, size of recurrence, disease status at last follow-up were found to be significant risk factors to predict optimal TC. Optimal cytoreduction in initial and tertiary surgery and serum CA-125 level prior to TC were independent prognostic factors on univariate analysis. Conclusions: Our results and a literature review clearly showed that maximal surgical effort should be made in TC, since patients undergoing optimal TC have a better survival. Thus, patients with secondary recurrent EOC in whom optimal cytoreduction can be achieved should be actively selected.
Ovarian cancer;recurrence;cytoreduction;surgery;survival;
 Cited by
Al Rawahi T, Lopes AD, Bristow RE, et al (2013). Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev, 2013, 2.

Arikan SK, Kasap B, Yetimalar H, et al (2014). Impact of prognostic factors on survival rates in patients with ovarian carcinoma. Asian Pac J Cancer Prev, 15, 6087-94. crossref(new window)

Benedet JL, Bender H, Jones 3rd H, et al (2000). FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet, 70, 209-62. crossref(new window)

Bristow RE, Tomacruz RS, Armstrong DK, et al (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 20, 1248-59. crossref(new window)

Chi DS, Eisenhauer EL, Lang J, et al (2006). What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol, 103, 559-64. crossref(new window)

Eisenkop SM, Friedman RL, Spirtos NM (2000). The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer, 88, 144-53. crossref(new window)

Fotopoulou C, Richter R, Braicu IE, et al (2011). Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer. Ann Surg Oncol, 18, 49-57. crossref(new window)

Fotopoulou C, Zang R, Gultekin M, et al (2013). Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann Surg Oncol, 20, 1348-54. crossref(new window)

Gultekin M, Velipasaoglu M, Aksan Guldeniz, et al (2008). A Third Evaluation of Tertiary Cytoreduction. J Surgical Oncol, 98, 530-4. crossref(new window)

Harter P, du Bois A, Hahmann M, et al ( 2006). Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol, 13, 1702-10. crossref(new window)

Hizli D, Boran N, Yilmaz S, et al (2012). Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol, 163, 71-5. crossref(new window)

Karam AK, Santillan A, Bristow RE, et al (2007). Tertiary cytoreductive surgery in recurrent ovarian cancer: Selection criteria and survival outcome. Gynecol Oncol, 104, 377-80. crossref(new window)

Leitao MM, Kardos S, Barakat RR, et al (2004). Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol, 95, 181-8. crossref(new window)

Maldonado G, Greenland S (1993). Simulation study of confounder-selection strategies. Am J Epidemiol, 138, 923-36. crossref(new window)

Sehouli J, Richter R, Braicu EI, et al (2010). Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol, 102, 656-62. crossref(new window)

Shih KK, Chi DS, Barakat RR, et al (2010). Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol, 117, 330-5. crossref(new window)

Tang J, Liu LD, Shu S, et al (2013). Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: Implications for tertiary cytoreductive surgery. EJSO, 39, 786-91. crossref(new window)

Zang RY, Li ZT, Tang J, et al (2004). Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer, 100, 1152-61. crossref(new window)